TY - JOUR
T1 - Open science precision medicine in Canada
T2 - Points to consider
AU - Moreno, Palmira Granados
AU - Ali-Khan, Sarah E.
AU - Capps, Benjamin
AU - Caulfield, Timothy
AU - Chalaud, Damien
AU - Edwards, Aled
AU - Gold, E. Richard
AU - Rahimzadeh, Vasiliki
AU - Thorogood, Adrian
AU - Auld, Daniel
AU - Bertier, Gabrielle
AU - Breden, Felix
AU - Caron, Roxanne
AU - César, Priscilla M.D.G.
AU - Cook-Deegan, Robert
AU - Doerr, Megan
AU - Duncan, Ross
AU - Issa, Amalia M.
AU - Reichman, Jerome
AU - Simard, Jacques
AU - So, Derek
AU - Vanamala, Sandeep
AU - Joly, Yann
N1 - Funding Information:
Launched in 2008, the Canadian Partnership for Tomorrow Project (CPTP) is Canada’s largest health research platform built to better understand and improve the treatment of cancer and chronic diseases. It collects, stores, and shares lifestyle and family history information, biosamples, and physical measurements from multiple provincial research projects and biobanks with the scientific community. It consists of five publicly funded provincial cohorts (BC Generations Project, Alberta’s Tomorrow Project, Ontario Health Study, CARTaGENE, and Atlantic PATH) and it has the support of at least 15 partner institutions, the University of Toronto being the most recent addition (Canadian Partnership for Tomorrow Project 2015a).
Publisher Copyright:
© 2018 Granados Moreno et al.
PY - 2019
Y1 - 2019
N2 - Open science can significantly influence the development and translational process of precision medicine in Canada. Precision medicine presents a unique opportunity to improve disease prevention and healthcare, as well as to reduce health-related expenditures. However, the development of precision medicine also brings about economic challenges, such as costly development, high failure rates, and reduced market size in comparison with the traditional blockbuster drug development model. Open science, characterized by principles of open data sharing, fast dissemination of knowledge, cumulative research, and cooperation, presents a unique opportunity to address these economic challenges while also promoting the public good. The Centre of Genomics and Policy at McGill University organized a stakeholders’ workshop in Montreal in March 2018. The workshop entitled “Could Open be the Yellow Brick Road to Precision Medicine?” provided a forum for stakeholders to share experiences and identify common objectives, challenges, and needs to be addressed to promote open science initiatives in precision medicine. The rich presentations and exchanges that took place during the meeting resulted in this consensus paper containing key considerations for open science precision medicine in Canada. Stakeholders would benefit from addressing these considerations as to promote a more coherent and dynamic open science ecosystem for precision medicine.
AB - Open science can significantly influence the development and translational process of precision medicine in Canada. Precision medicine presents a unique opportunity to improve disease prevention and healthcare, as well as to reduce health-related expenditures. However, the development of precision medicine also brings about economic challenges, such as costly development, high failure rates, and reduced market size in comparison with the traditional blockbuster drug development model. Open science, characterized by principles of open data sharing, fast dissemination of knowledge, cumulative research, and cooperation, presents a unique opportunity to address these economic challenges while also promoting the public good. The Centre of Genomics and Policy at McGill University organized a stakeholders’ workshop in Montreal in March 2018. The workshop entitled “Could Open be the Yellow Brick Road to Precision Medicine?” provided a forum for stakeholders to share experiences and identify common objectives, challenges, and needs to be addressed to promote open science initiatives in precision medicine. The rich presentations and exchanges that took place during the meeting resulted in this consensus paper containing key considerations for open science precision medicine in Canada. Stakeholders would benefit from addressing these considerations as to promote a more coherent and dynamic open science ecosystem for precision medicine.
KW - Canadian health policies
KW - Open science
KW - Open science in precision medicine
KW - Precision medicine
KW - Valorisation
UR - http://www.scopus.com/inward/record.url?scp=85083875728&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083875728&partnerID=8YFLogxK
U2 - 10.1139/facets-2018-0034
DO - 10.1139/facets-2018-0034
M3 - Review article
AN - SCOPUS:85083875728
SN - 2371-1671
VL - 4
SP - 1
EP - 19
JO - Facets
JF - Facets
IS - 1
ER -